U.S. Adrenocortical Carcinoma Treatment Market Size, Share & Forecast 2026–2032

ID: MR-11344 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Adrenocortical Carcinoma Treatment Market
  • ✓Market Size 2024: USD 212 million
  • ✓Market Size 2032: USD 318 million
  • ✓CAGR: 5.2%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Single-Agent Dependence Risk: Mitotane, marketed as Lysodren by Recordati Rare Diseases since its 1970 FDA approval, remains the only agent with a specific ACC indication. Its narrow therapeutic index demands plasma monitoring in CLIA-certified laboratories, making diagnostic lab access a hidden bottleneck.
FINDING 02
Orphan Pricing Assumption Challenged: Analysts assume the Inflation Reduction Act shields rare-cancer revenue from Medicare price negotiation. The orphan exclusion, expanded by Public Law 119-21, applies only while a product holds orphan-only approvals, so ACC sponsors seeking broader tumor indications face negotiation exposure.
ANALYST RECOMMENDATION

Analyst Recommendation — Secure Diagnostic Lab Partnerships: Sponsors and investors should contract CLIA-certified mitotane monitoring capacity with two academic centers before Q1 2027. Single-laboratory dependence delays dosing decisions, and serum levels between 14 and 20 mg/L determine both efficacy and neurotoxicity.

Adrenocortical Carcinoma Care in the U.S.: Market Overview

The U.S. adrenocortical carcinoma (ACC) treatment market is small and tightly concentrated, with an estimated 2024 value of USD 212 million. Incidence of roughly one to two cases per million people annually limits the patient base to several hundred new diagnoses each year. Mitotane, the only agent with a specific FDA indication for ACC since 1970, anchors demand in every treatment pathway, so commercial volume depends on sustained access to a single molecule.

Government has been the dominant force in shaping the market's structure, while the private sector has led commercial supply. The National Cancer Institute funds much of the investigator-initiated research through NCI-designated cancer centers, and the FDA Office of Orphan Products Development grants orphan designation under the Orphan Drug Act of 1983. Recordati Rare Diseases has led commercialization of Lysodren and also markets osilodrostat (Isturisa) for the cortisol excess that many ACC patients develop.

Policy-Driven Growth in Adrenocortical Carcinoma Care

Three policy mechanisms drive demand. First, the Orphan Drug Act of 1983 grants seven years of market exclusivity and a 50 percent federal tax credit on qualified clinical testing costs under Internal Revenue Code Section 45C, lowering sponsor risk for ACC trials. Second, the Food and Drug Omnibus Reform Act of 2022 (FDORA) strengthened FDA's accelerated approval authority, giving sponsors faster routes to market for ACC agents validated against surrogate endpoints.

Third, the Medicare Part D redesign under the Inflation Reduction Act of 2022 caps beneficiary out-of-pocket spending at USD 2,000 in 2025, rising to USD 2,100 in 2026. Mitotane is an oral drug covered under Part D, so the cap directly lifts adherence. Lower cost-sharing converts prescribed courses into continuous therapy, expanding paid units without expanding the diagnosed population.

Regulatory Barriers and Compliance Costs

Therapeutic drug monitoring creates the most immediate compliance burden. Mitotane requires plasma level measurement against a target range of 14 to 20 mg/L, performed in laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 and overseen by the Centers for Medicare and Medicaid Services. Few reference laboratories offer validated assays, and multi-day delays between sampling and results postpone dose adjustments that determine both efficacy and neurotoxicity.

Hazardous drug handling adds cost at dispensing. Mitotane and cytotoxic regimens such as etoposide, doxorubicin, and cisplatin fall under the NIOSH List of Hazardous Drugs and the OSHA Hazard Communication Standard at 29 CFR 1910.1200, requiring documented staff training and controlled compounding. State boards of pharmacy add licensing obligations for specialty dispensing, creating administrative overhead that smaller community practices often cannot absorb.

Policy-Created Opportunities for Adrenocortical Carcinoma in the U.S.

FDA's Oncology Center of Excellence creates opportunity for sponsors developing second-line agents. Project Orbis, launched in 2019, enables concurrent review with regulators in Australia, Canada, Singapore, Switzerland, Brazil, and the United Kingdom, so a U.S. approval for an ACC agent can trigger parallel submissions abroad. Sponsors that run trials through NCI cooperative groups can also build the evidence base needed for accelerated approval.

Medicare's negotiation exclusion for orphan-only products creates a second opportunity. Under the orphan provision expanded by Public Law 119-21, an ACC-specific therapy holding only orphan approvals remains outside Medicare price negotiation, allowing sponsors to price for scarcity. Sponsors should also target 340B-covered cancer centers administered by HRSA, which acquire high-cost oral oncology agents at discounted prices and therefore prioritize them for institutional formularies.

Market at a Glance

MetricValue
Market Size 2024USD 212 million
Market Size 2032USD 318 million
Growth Rate (CAGR)5.2%
Most Critical Decision FactorAccess to CLIA-certified therapeutic drug monitoring
Largest RegionNortheast United States
Competitive StructureConcentrated; one dominant marketed agent

Leading Market Participants

  • Recordati Rare Diseases
  • Bristol Myers Squibb
  • Merck & Co.
  • Novartis
  • Pfizer
  • Eli Lilly and Company
  • Bayer
  • Ipsen
  • Exelixis
  • Sandoz

Regulatory and Policy Environment

The primary legislation governing ACC therapeutics is the Federal Food, Drug, and Cosmetic Act, as amended by the Orphan Drug Act of 1983, FDORA 2022, and the Prescription Drug User Fee Act (PDUFA VII), which funds review through fiscal year 2027. FDA's Center for Drug Evaluation and Research and the Office of Orphan Products Development administer approvals and designations under 21 CFR Part 316. Key compliance requirements include orphan designation filings, Investigational New Drug submissions under 21 CFR Part 312, and FDORA-mandated confirmatory trials for accelerated approvals.

Upcoming changes include PDUFA VIII negotiations ahead of the September 30, 2027 expiry of PDUFA VII, and Medicare negotiation cycles administered by CMS, where the selected-drug list for initial price applicability year 2028 is due by February 1, 2026. Compared with regional peers, the U.S. offers seven years of orphan exclusivity, against ten years under Regulation (EC) No 141/2000 in the European Union. Canada's Special Access Programme and Japan's PMDA orphan designation provide narrower commercial protection.

Long-Term Policy Outlook for Adrenocortical Carcinoma in the U.S.

By 2032, Medicare price negotiation will reach oncology products whose orphan status lapses after a non-orphan approval, shifting ACC economics toward volume-based pricing. Mitotane's commercial value will erode as exclusivity matures, making sponsor portfolios that include combination regimens and second-line agents more resilient. Rare-cancer revenue strategies will therefore depend on managing the boundary between orphan-only and broader indications.

Policy will also reshape diagnostic access. CMS reimbursement under the Clinical Laboratory Fee Schedule and CLIA oversight will determine whether therapeutic drug monitoring for mitotane scales nationally. FDA's continued expansion of rare-disease evidence frameworks will widen approval pathways for ACC combination regimens and immune checkpoint inhibitors, shifting growth toward earlier-line and maintenance therapy.

Frequently Asked Questions

The FDA Office of Orphan Products Development grants orphan designation under 21 CFR Part 316 for conditions affecting fewer than 200,000 Americans. Sponsors submit requests with epidemiological evidence supporting the rare-disease threshold.
Products holding only orphan approvals are excluded from Medicare negotiation under the orphan provision expanded by Public Law 119-21. Exposure begins once a product gains a non-orphan approval.
Plasma mitotane testing must be performed in laboratories holding a CLIA certificate issued under the Clinical Laboratory Improvement Amendments of 1988. Laboratories must meet CMS quality, personnel, and proficiency testing standards.
The Inflation Reduction Act caps beneficiary out-of-pocket spending at USD 2,100 in 2026, up from USD 2,000 in 2025. The cap applies to oral mitotane covered under Part D.
The U.S. grants seven years of orphan market exclusivity under the Orphan Drug Act of 1983. The European Union grants ten years under Regulation (EC) No 141/2000.

Market Segmentation

By Therapy Type
  • Mitotane Monotherapy
  • EDP-Mitotane Combination
  • Streptozocin-Based Chemotherapy
  • Immune Checkpoint Inhibitors
By Payer
  • Medicare Part D
  • Medicaid
  • Commercial Insurance
  • 340B Covered Entities

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 United States Adrenocortical Carcinoma Treatment Market - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Therapy Type Insights
4.1 Mitotane Monotherapy
4.2 EDP-Mitotane Combination
4.3 Streptozocin-Based Chemotherapy
4.4 Immune Checkpoint Inhibitors
4.5 Others
Chapter 05 Payer Insights
5.1 Medicare Part D
5.2 Medicaid
5.3 Commercial Insurance
5.4 340B Covered Entities
5.5 Others
Chapter 06 Competitive Landscape
6.1 Market Players
6.2 Leading Market Participants
6.2.1 Recordati Rare Diseases
6.2.2 Bristol Myers Squibb
6.2.3 Merck & Co.
6.2.4 Novartis
6.2.5 Pfizer
6.2.6 Eli Lilly and Company
6.2.7 Bayer
6.2.8 Ipsen
6.2.9 Exelixis
6.2.10 Sandoz
6.3 Regulatory Environment
6.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.